Adiposs is a technology company.
Adiposs is a biotech start-up company, a spin-off from the University of Geneva, focused on developing advanced nanotechnology pharmaceutical systems and medical imaging agents.
Adiposs has raised $2.0M across 1 funding round.
Adiposs has raised $2.0M in total across 1 funding round.
Adiposs has raised $2.0M in total across 1 funding round.
Adiposs's investors include Privilège Ventures.
Adiposs is a clinical-stage Swiss medtech startup developing ImageBAT, the first-in-class CT contrast agent for visualizing brown adipose tissue (BAT) to enable early detection of cachexia—a severe body wasting condition linked to cancer and chronic diseases.[1][2][4] It serves healthcare providers, hospitals, and patients at risk of cancer progression, treatment failure, or metabolic disorders by offering a simple, non-invasive add-on to standard CT/PET-CT scans available worldwide, predicting therapy response and personalizing treatment to improve survival and quality of life.[2][4][5] With Phase 1 clinical trials completed, recent CHF 4 million funding, and recognition as a top Swiss innovator, Adiposs shows strong growth momentum, including pre-Series A rounds and pitching successes.[2][5][6]
Adiposs emerged as a spin-off from the University of Geneva, founded by a core team of four biotech entrepreneurs with over 80 years of combined experience in drug development and multiple successful exits.[1][4] The idea stemmed from addressing a critical gap: 20 million annual cancer diagnoses, with 2 out of 3 patients failing therapy due to undetected cachexia, where brown fat serves as an early biomarker.[4][5] Early traction included securing CHF 100,000 initial funding, Innosuisse certification, Venture Kick Stage 3 win, and dosing the first subject in Phase 1 trials, followed by completion of those trials and progressive funding rounds up to CHF 4 million for advancing clinical development and industrialization.[5]
Adiposs rides the wave of precision oncology and metabolic imaging, where early cachexia detection can stratify cancer patients for personalized therapies amid rising global cancer burdens (10 million deaths yearly).[4][5] Timing aligns with advances in CT/PET imaging ubiquity and demand for non-invasive biomarkers, fueled by market forces like aging populations, chronic disease prevalence, and post-pandemic focus on efficient diagnostics.[1][3] By enabling therapy response prediction, it influences the ecosystem through partnerships in cachexia management, oncology KOL collaborations, and contributions to medtech hubs like Swiss Biotech and BioAlps, potentially reducing treatment failures and healthcare costs.[1][3]
Adiposs is poised to disrupt cancer care with ImageBAT's rollout into Phase 2 trials and industrialization, leveraging its funding and awards to scale globally.[5] Trends like AI-enhanced imaging, expanded BAT research in metabolic diseases, and regulatory pushes for companion diagnostics will propel it, potentially evolving its influence from niche innovator to standard-of-care enabler in oncology.[2][4] As it builds on its University of Geneva roots and biotech expertise, Adiposs exemplifies how targeted medtech can turn early detection into lifesaving momentum.
Adiposs has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $2.0M Seed | Privilège Ventures |